Price$5.26+0.63 (+13.60%)
2026-03-062026-06-09
News · 26 weeks53-23%
2025-12-142026-06-07
Mix3090d
- Other11(37%)
- Insider10(33%)
- SEC Filings7(23%)
- Earnings2(7%)
Latest news
25 items- SECSEC Form 8-K filed by Nuvation Bio Inc.8-K - Nuvation Bio Inc. (0001811063) (Filer)
- PRNuvation Bio to Present at the Jefferies Global Healthcare ConferenceNEW YORK, May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 9:55 a.m. ET in New York, NY. A live webcast of the fireside chat will be available on the Investor Relations section of the Nuvation Bi
- PRNuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting88% of TRUST-II patients reported improved or stable quality of life at first assessment, with the majority sustaining that benefit throughout treatmentCognitive function scores improved or remained stable throughout the course of treatment with IBTROZIIBTROZI provided rapid relief from burdensome symptoms, including cough and shortness of breathNEW YORK, May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new patient-reported outcomes data from the pivotal TRUST-II study of IBTROZI® (taletrectinib) in patients with advanced ROS1-positive (ROS1+) non-small cell lung can
- INSIDERSEC Form 4 filed by Director Vernon W Anthony4 - Nuvation Bio Inc. (0001811063) (Issuer)
- INSIDERSEC Form 4 filed by Director Mashal Robert4 - Nuvation Bio Inc. (0001811063) (Issuer)
- INSIDERSEC Form 4 filed by Director Falberg Kathryn E4 - Nuvation Bio Inc. (0001811063) (Issuer)
- INSIDERSEC Form 4 filed by Director Blickenstaff Kim D4 - Nuvation Bio Inc. (0001811063) (Issuer)
- INSIDERSEC Form 4 filed by Director Bazemore Robert B4 - Nuvation Bio Inc. (0001811063) (Issuer)
- INSIDERSEC Form 4 filed by Director Cui Xiangmin4 - Nuvation Bio Inc. (0001811063) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Cui Xiangmin4/A - Nuvation Bio Inc. (0001811063) (Issuer)
- PRNuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung CancerThermo Fisher Scientific, the world leader in serving science, will now manufacture drug product for Nuvation Bio in the United StatesMove by Nuvation Bio further ensures critical drug supply for patients and providersNEW YORK, May 13, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the successful completion of process tech transfer and product introduction to Thermo Fisher Scientific, the world leader in serving science, for IBTROZI® (taletrectinib) to treat advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The transition was submitted as a su
- PRNuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung CancerApplication includes updated TRUST-I TKI-naïve median duration of response (mDOR) and median progression-free survival (mPFS) of more than 4 years, as well as TRUST-II TKI-pretreated mDOR of nearly 20 months FDA has assigned a target action date of January 4, 2027NEW YORK, May 6, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) with updated data for IBTROZI® (taletrectinib) in both TKI-naïve and TKI-pretreated advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCL
- PRNuvation Bio to Participate in Upcoming Investor ConferencesNEW YORK, May 5, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats and one-on-one meetings at the following conferences: Bank of America Securities 2026 Healthcare Conference – fireside chat on Wednesday, May 13, 2026, at 8:00 a.m. PT in Las Vegas, NVH.C. Wainwright 4th Annual BioC
- SECSEC Form 8-K filed by Nuvation Bio Inc.8-K - Nuvation Bio Inc. (0001811063) (Filer)
- PRNuvation Bio Reports First Quarter 2026 Financial Results and Provides Business UpdateAchieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI® (taletrectinib); majority of the approximately 200 patients started on IBTROZI in the first quarter of 2026 were TKI-naïve, highlighting continued momentum in the first-line settingPresented newly updated clinical data demonstrating IBTROZI's impressive durability of response and progression-free survival in TKI-naïve and TKI-pretreated patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) at AACR 2026 Announced acquisition of Japan rights to safusidenib from Daiichi Sankyo, enabling global development and commercialization of promising investigational medicineStrong balance sheet with
- SECSEC Form 10-Q filed by Nuvation Bio Inc.10-Q - Nuvation Bio Inc. (0001811063) (Filer)
- PRNuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System CancersGuidelines include the next-generation targeted therapy as a systemic option for patients with ROS1-positive non-small cell lung cancer with brain metastasesNEW YORK, April 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that taletrectinib (IBTROZI®) has been added to the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines®) in Oncology for Central Nervous System (CNS) cancers, updated on April 24, 2026. Specifically, the NCCN Guidelines® for CNS Cancers now recommend taletrectinib (IBTROZI) as a systemic therapy option for ROS1-po
- PR/U P D A T E -- Nuvation Bio Inc./In the news release, Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026, issued April 21, 2026 by Nuvation Bio Inc. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026 Analysis of longer-term pooled data from TRUST-I and TRUST-II demonstrated nearly 50 months median duration of response and 46.1 months median progression-free survival in
- PRNuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026Analysis of longer-term pooled data from TRUST-I and TRUST-II demonstrated nearly 50 months median duration of response and 46.1 months median progression-free survival in TKI-naïve patientsIBTROZI also demonstrated a high overall response rate in TKI-naïve patients at 89.8%Long-term pooled data highlighted in oral and poster presentations at AACR, and TRUST-I data simultaneously published in the Journal of Clinical Oncology, reinforce IBTROZI's manageable safety profile, with low rates of neurologic side effects and no new safety signalsIBTROZI demonstrated robust CNS activity, with an intracranial response rate of 76.5% in TKI-naïve patients and 65.6% in TKI-pretreated patients with brain
- INSIDERSEC Form 4 filed by Wentworth Kerry4 - Nuvation Bio Inc. (0001811063) (Issuer)
- INSIDERSEC Form 4 filed by Liu Dongfang4 - Nuvation Bio Inc. (0001811063) (Issuer)
- SECSEC Form DEFA14A filed by Nuvation Bio Inc.DEFA14A - Nuvation Bio Inc. (0001811063) (Filer)
- PRNuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026NEW YORK, April 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, May 4, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the first quarter of 2026. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-461-5787 (
- SECSEC Form 144 filed by Nuvation Bio Inc.144 - Nuvation Bio Inc. (0001811063) (Subject)
- SECSEC Form DEF 14A filed by Nuvation Bio Inc.DEF 14A - Nuvation Bio Inc. (0001811063) (Filer)
NUVB FAQ
7 questionsWhat does Nuvation Bio Inc. do?
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to androgen receptor-expressing cancer cells...Where does NUVB stock trade?
Nuvation Bio Inc. (NUVB) is listed on NYSE.What sector and industry is NUVB in?
Nuvation Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Nuvation Bio Inc. go public?
Nuvation Bio Inc. (NUVB) completed its IPO in 2020.What are analysts saying about NUVB?
Nuvation Bio Inc. has had 8 recent analyst actions on file. The most recent action was from Truist: Buy on 2025-11-24.What companies are similar to NUVB?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NUVB side-by-side with any of them on Quantisnow.How can I track NUVB on Quantisnow?
Quantisnow aggregates Nuvation Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NUVB to receive live email and push alerts on every new disclosure.